Andere Kunden interessierten sich auch für
![Bioequivalence and Bioavailability studies in Human Volunteers]( "Bioequivalence and Bioavailability studies in Human Volunteers")
Bioequivalence and Bioavailability studies in Human Volunteers32,99 €![BIOPHARMACEUTICS AND PHARMACOKINETICS -VIVA VOCE QUESTIONS AND ANSWERS]( "BIOPHARMACEUTICS AND PHARMACOKINETICS -VIVA VOCE QUESTIONS AND ANSWERS")
BIOPHARMACEUTICS AND PHARMACOKINETICS -VIVA VOCE QUESTIONS AND ANSWERS26,99 €![Design and Analysis of Bioavailability and Bioequivalence Studies]( "Design and Analysis of Bioavailability and Bioequivalence Studies")
Design and Analysis of Bioavailability and Bioequivalence Studies207,99 €![Bioequivalence Study of Sustained-Release Tablets]( "Bioequivalence Study of Sustained-Release Tablets")
Bioequivalence Study of Sustained-Release Tablets26,99 €![The Bioequivalence of Doxazosin Slow Release Tablets: A Pilot Study]( "The Bioequivalence of Doxazosin Slow Release Tablets: A Pilot Study")
The Bioequivalence of Doxazosin Slow Release Tablets: A Pilot Study44,99 €![Bioequivalence Study of Antihyperlipidemic in Human Volunteers]( "Bioequivalence Study of Antihyperlipidemic in Human Volunteers")
Bioequivalence Study of Antihyperlipidemic in Human Volunteers32,99 €![Quality of Anti Hypertensive Drugs]( "Quality of Anti Hypertensive Drugs")
Quality of Anti Hypertensive Drugs32,99 €
The present study has been undertaken with following objectives: To assess the bioequivalence of Gabapentin 600 mg Tablet (Test formulation, Torrent Pharmaceuticals Ltd., India) versus Neurontin® 600mg Tablet (Reference formulation, Pfizer, Brazil) in healthy human volunteers after administration of single Tablet of either test or reference formulation under fasting condition. The secondary objective was to evaluate the safety of Gabapentin in healthy human volunteers on the basis of clinical and laboratory examinations (at the beginning and at the end of the trial) and registration of adverse events and/or adverse drug reactions in healthy human volunteers after administration of single tablet of either test or reference formulation under fasting conditions.